Three clinical-stage companies, Minerva Neurosciences Inc., Cymabay Therapeutics Inc. and Dance Biopharm Inc. filed for initial public offerings (IPO) on Nasdaq in hopes of harnessing millions of dollars from enthusiastic investors and riding momentum from a first quarter in which 28 biotech IPOs raised $2.2 billion.